Growth Control Mechanisms in Multiple Myeloma

References

• Barlogie B., Epstein J., Selvanayagam P., Alexanian R. Plasma cell myeloma-new biological insights and advances in therapy. Blood 1989; 73: 865–879
   PubMed Web of Science ®Google Scholar
• Mandelli F., Avvisati G., Tribalto M. Biology and treatment of multiple myeloma. Curr. Opin. Oncol. 1992; 4: 73–86
   PubMedGoogle Scholar
• Bakkus M. H. C., Van Riet I., De Greef C., Van Camp B., Thielemans K. The clonogenic precursor cell in multiple myeloma. Leuk. Lymphoma 1995; 18: 221–229
   PubMed Web of Science ®Google Scholar
• Bakkus M. H., Heirman C., Van Riet I., Van Camp B., Thielemans K. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 1992; 80: 2326–2335
   PubMed Web of Science ®Google Scholar
• Billadeau D., Ahmann G., Griepp P., Van Ness B. The bone marrow of multiple myeloma patients contains B-cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J. Exp. Med. 1993; 178: 1023–1031
   PubMed Web of Science ®Google Scholar
• Van Riet I., Van Camp B. The involvement of adhesion molecules in the biology of multiple myeloma. Leuk. Lymphoma 1993; 9: 441–452
   PubMed Web of Science ®Google Scholar
• Okada T., Hawley R. G. Adhesion molecules involved in the binding of murine myeloma cells to bone marrow stromal elements. Int. J. Cancer 1995; 63: 823–830
   PubMed Web of Science ®Google Scholar
• Durie B. G., Salmon S. E. Cellular kinetics staging, and immunoglobulin synthesis in multiple myeloma. Ann. Rev. Med. 1975; 26: 283–288
   PubMed Web of Science ®Google Scholar
• San Miguel J. F., Garcia-Sanz R., Gonzalez M., Moro M. J., Hernandez J. M., Ortega F., Borrego D., Carnero M., Casanova F., Jimeniz R., Portero J. A., Orfao A. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 1995; 85: 448–455
   PubMed Web of Science ®Google Scholar
• Alexanian R., Dimopoulos M. The treatment of multiple myeloma. New Eng. J. Med. 1994; 330: 484–489
   PubMed Web of Science ®Google Scholar
• Tricot G., Jagannath S., Vesole D. H., Bracy D., Desikan K. R., Siegel D., Barlogie B. Hematopoietic stem cell transplants for multiple myeloma. Leuk. Lymphoma 1996; 22: 25–36
   PubMed Web of Science ®Google Scholar
• Couban S., Stewart A. K., Loach D., Panzarella T., Meharchand J. Autologous and allogeneic transplantation for multiple myeloma at a single centre. Bone Marrow Transplant 1997; 19: 783–789
   PubMed Web of Science ®Google Scholar
• Klein B., Zhang X.-G., Lu Z.-Y., Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995; 85: 863–872
   PubMed Web of Science ®Google Scholar
• Kishimoto T., Akira S., Narazaki M., Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995; 86: 1243–1254
   PubMed Web of Science ®Google Scholar
• Palumbo A., Bruno B., Boccadoro M., Pileri A. Interferon-γ in multiple myeloma. Leuk. Lymphoma 1995; 18: 215–219
   PubMed Web of Science ®Google Scholar
• Peest D., Blade J., Harousseau J.-L., Klein B., Osterborg A., San Miguel J. F. Cytokine therapy in multiple myeloma. Br. J. Haematol. 1996; 94: 425–432
   PubMed Web of Science ®Google Scholar
• Hawley R. G. Hematopathology of interleukin-6-type cytokines. Stem Cells 1994; 12(suppl. 1)155–171
   PubMed Web of Science ®Google Scholar
• Taga T., Kishimoto T. GP130 and the interleukin-6 family of cytokines. An. Rev. Immunol. 1997; 15: 797–819
   PubMed Web of Science ®Google Scholar
• Van Snick J. Interleukin-6: an overview. Ann. Rev. Immunol. 1990; 8: 253–278
   PubMed Web of Science ®Google Scholar
• Hirano T., Akira S., Taga T., Kishimoto T. Biological and clinical aspects of interleukin 6. Immunol. Today 1990; 11: 443–449
   PubMedGoogle Scholar
• Hawley R. G. Interleukin-6-type cytokines in myeloproliferative disease. Ann. N.Y. Acad. Sci. 1995; 762: 294–307
   PubMed Web of Science ®Google Scholar
• Haegeman G., Content J., Volckaert G., Derynck R., Tavernier J., Fiers W. Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts. Eur. J. Biochem. 1986; 159: 625–632
   PubMedGoogle Scholar
• Zilberstein A., Ruggieri R., Korn J. H., Revel M. Structure and expression of cDNA and genes for human interferon-β-2, a distinct species inducible by growth-stimulatory cytokines. EMBO J. 1986; 5: 2529–2537
   PubMed Web of Science ®Google Scholar
• May L. T., Helfgott D. C., Sehgal P. B. Anti-β-interferon antibodies inhibit the increased expression of HLA-B7 mRNA in tumor necrosis factor-treated human fibroblasts:structural studies of the beta2 interferon involved. Proc. Natl. Acad. Sci. USA 1986; 83: 8957–8961
   PubMed Web of Science ®Google Scholar
• Gauldie J., Richards C., Harnish D., Lansdorp P., Baumann H. Interferon β2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc. Natl. Acad. Sci. USA 1987; 84: 7251–7255
   PubMed Web of Science ®Google Scholar
• Garman R. D., Jacobs K. A., Clark S. C., Raulet D. H. B-cell-stimulatory factor 2 (β2 interferon) functions as a second signal for interleukin 2 production by mature murine T-cells. Proc. Natl. Acad. Sci. USA 1987; 84: 7629–7633
   PubMed Web of Science ®Google Scholar
• Wong G. G., Witek-Giannotti J. S., Temple P. A., Kriz R., Ferenz C., Hewick R. M., Clark S. C., Ikebuchi K., Ogawa M. Stimulation of murine hemopoietic colony formation by human IL-6. J. Immunol. 1988; 140: 3040–3044
   PubMed Web of Science ®Google Scholar
• Hirano T., Yasukawa K., Harada H., Taga T., Watanabe Y., Matsuda T., Kashiwamura S., Nakajima K., Koyama K., Iwamatsu A., Tsunasawa S., Sakiyama F., Matsui H., Takahara Y., Taniguchi T., Kishimoto T. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324: 73–76
   PubMed Web of Science ®Google Scholar
• Nordan R. P., Potter M. A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. Science 1986; 233: 566–569
   PubMed Web of Science ®Google Scholar
• Van Snick J., Vink A., Cayphas S., Uyttenhove C. Interleukin-HP1, a T-cell-derived hybridoma growth factor that supports the in vitro growth of murine plasmacytomas. J. Exp. Med. 1987; 165: 641–649
   PubMed Web of Science ®Google Scholar
• Van Damme J., Opdenakker G., Simpson R. J., Rubira M. R., Cayphas S., Vink A., Billiau A., Van Snick J. Identification of the human 26-kD protein, interferon β2 (IFN-βs), as a B-cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor. J. Exp. Med. 1987; 165: 914–919
   PubMed Web of Science ®Google Scholar
• Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H., Kuramoto A., Kishimoto T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83–85
   PubMed Web of Science ®Google Scholar
• Klein B., Zhang X. G., Jourdan M., Content J., Houssiau F., Aarden L., Piechaczyk M., Bataille R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989; 73: 517–526
   PubMed Web of Science ®Google Scholar
• Hitzler J. K., Martinez-Valdes H., Bergsagel D. B., Minden M. D., Messner H. A. Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease. Blood 1991; 78: 1996–2004
   PubMed Web of Science ®Google Scholar
• Jelinek D. F., Ahmann G. J., Greipp P. R., Jalal S. M., Westendorf J. J., Katzmann J. A., Kyle R. A., Lust J. A. Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. Cancer Res. 1993; 53: 5320–5327
   Google Scholar
• Zhang X.-G., Gaillard J. P., Robillard N., Lu Z.-Y., Gu Z.-J., Jourdan M., Boiron J. M., Bataille R., Klein B. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in multiple myeloma. Blood 1994; 83: 3654–3663
   PubMed Web of Science ®Google Scholar
• Zhang X. G., Klein B., Bataille R. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 1989; 74: 11–13
   PubMed Web of Science ®Google Scholar
• Bataille R., Jourdan M., Zhang X. G., Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J. Clin. Invest. 1989; 84: 2008–2011
   PubMed Web of Science ®Google Scholar
• Klein B., Zhang X. G., Jourdan M., Portier M., Bataille R. Interleukin-6 is a major myeloma cell growth factor in vitro, in vivo especially in patients with terminal disease. Curr. Top. Microbiol. Immunol. 1990; 166: 23–32
   PubMed Web of Science ®Google Scholar
• Paul S. R., Bennett F., Calvetti J. A., Kelleher K., Wood C. R., O'Hara R. M., Jr., Leary A. C., Sibley B., Clark S. C., Williams D. A., Yang Y.-C. Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc. Natl. Acad. Sci. USA 1990; 87: 7512–7516
   PubMed Web of Science ®Google Scholar
• Hawley R. G., Fong A. Z. C., Ngan B. Y., De Lanux V. M., Clark S. C., Hawley T. S. Progenitor cell hyperplasia with rare development of myeloid leukemia in interleukin 11 bone marrow chimeras. J. Exp. Med. 1993; 178: 1175–1188
   PubMed Web of Science ®Google Scholar
• Berger L. C., Hawley T. S., Lust J. A., Goldman S. J., Hawley R. G. Tyrosine phosphorylation of JAK-TYK kinases in malignant plasma cell lines growth-stimulated by interleukins 6 and 11. Biochem. Biophys. Res. Commun. 1994; 202: 596–605
   PubMed Web of Science ®Google Scholar
• Zhang X.-G., Gu J.-J., Lu Z.-Y., Yasukawa K., Yancopoulos G. D., Turner K., Shoyab M., Taga T., Kishimoto T., Bataille R., Klein B. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer GP130. J. Exp. Med. 1994; 177: 1337–1342
   Web of Science ®Google Scholar
• Nishimoto N., Ogata A., Shima Y., Tani Y., Ogawa H., Nakagawa M., Sugiyama H., Yoshizaki K., Kishimoto T. Oncostatin M., leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, GP130. J. Exp. Med. 1994; 179: 1343–1347
   PubMed Web of Science ®Google Scholar
• Lu Z.-Y., Gu Z.-J., Zhang X.-G., Wijdenes J., Neddermann P., Rossi J.-F., Klein B. Interleukin-10 induces interleukin-11 responsiveness in human myeloma cell lines. FEBS Lett. 1995; 377: 515–518
   PubMed Web of Science ®Google Scholar
• Gu Z.-J., Costes V., Lu Z.-Y., Zhang X.-G., Pitard V., Moreau J.-F., Bataille R., Wijdenes J., Rossi J.-F., Klein B. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood 1996; 88: 3972–3986
   PubMed Web of Science ®Google Scholar
• Cozzolino F., Torcia M., Aldinucci D., Rubartelli A., Miliani A., Shaw A. R., Lansdorp P. M., Di Guglielmo R. Production of interleukin-1 by bone marrow myeloma cells. Blood 1989; 74: 380–387
   PubMed Web of Science ®Google Scholar
• Kawano M., Yamamoto I., Iwato K., Tanaka H., Asaoku H., Tanabe O., Ishikawa H., Nobuyoshi M., Ohmoto Y., Hirai Y., Kuramoto A. Interleukin-1β rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma. Blood 1989; 73: 1646–1649
   PubMed Web of Science ®Google Scholar
• Hawley T. S., Lach B., Burns B. F., May L. T., Sehgal P. B., Hawley R. G. Expression of retrovirally transduced IL-1α in IL-6-dependent B-cells: A murine model of aggressive multiple myeloma. Growth Factors 1991; 5: 327–338
   PubMedGoogle Scholar
• Akira S., Hiran T., Taga T., Kishimoto T. Biology of multifunctional cytokines: IL-6 and related molecules (IL-1 and TNF). FASEB J. 1990; 4: 2860–2867
   PubMed Web of Science ®Google Scholar
• Ishikawa H., Tanaka H., Iwato K., Tanabe O., Asaoku H., Nobuyoshi M., Yamamoto I., Kawano M., Kuramoto A. Effect of glucocorticoids on the biologic activities of myeloma cells: inhibition of interleukin-1β osteoclast activating factor-induced bone resorption. Blood 1990; 75: 715–720
   PubMed Web of Science ®Google Scholar
• Zhang X.-G., Bataille R., Jourdan M., Saeland S., Banchereau J., Mannoni P., Klein B. Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood 1990; 76: 2599–2605
   PubMed Web of Science ®Google Scholar
• Kobayashi M., Tanaka J., Imamura M., Maeda S., Iwasaki H., Tanaka M., Tsudu Y., Sakurada K., Miyazaki T. Upregulation of IL-6 receptors by IL-3 on a plasma cell leukemia cell line which proliferates dependently on both IL-3 and IL-6. Br. J. Haematol. 1993; 83: 535–538
   PubMed Web of Science ®Google Scholar
• Georgii-Hemming P., Wiklund H. J., Ljunggren O., Nilsson K. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood 1996; 88: 2250–2258
   PubMed Web of Science ®Google Scholar
• Tanabe O., Akira S., Kamiya T., Wong G. G., Hirano T., Kishimoto T. Genomic structure of the murine IL-6 gene. J. Immunol. 1988; 141: 3875–3881
   PubMed Web of Science ®Google Scholar
• Matsusaka T., Fujikawa K., Nishio Y., Mukaida N., Matsushima K., Kishimoto T., Akira S. Transcription factors NF-IL6 and NF-kB synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc. Natl. Acad. Sci. USA 1993; 90: 10193–10197
   PubMed Web of Science ®Google Scholar
• Brach M. A., Gruss H.-J., Kaisho T., Asano Y., Hirano T., Herrmann F. Ionizing radiation induces expression of interleukin 6 by human fibroblasts involving activation of nuclear factor-kB. J. Biol. Chem. 1993; 268: 8466–8472
   PubMed Web of Science ®Google Scholar
• Dendorfer U., Oettgen P., Libermann T. A. Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. Mol. Cell. Biol. 1994; 14: 4443–4454
   PubMed Web of Science ®Google Scholar
• Portier M., Moles J.-P., Mazars G.-R., Jeanteur P., Bataille R., Klein B., Theillet C. p53 and RAS gene mutations in multiple myeloma. Oncogene 1992; 7: 2539–2543
   PubMed Web of Science ®Google Scholar
• Corradini P., Ladetto M., Voena C., Palumbo A., Inghirami G., Knowles D. M., Boccardoro M., Pileri A. Mutational activation of N-and K-ras oncogenes in plasma cell dyscrasias. Blood 1993; 81: 2708–2713
   PubMed Web of Science ®Google Scholar
• Demetri G. D., Ernst T. J., Pratt E. S., II, Zenzie B. W., Rheinwald J. G., Griffin J. D. Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes. J. Clin. Invest. 1990; 86: 1261–1269
   PubMed Web of Science ®Google Scholar
• Smeal T., Binetruy B., Mercola D. A., Birrer M., Karin M. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature 1991; 354: 494–496
   PubMed Web of Science ®Google Scholar
• Nakajima T., Kinoshita S., Sasagawa T., Sasaki K., Naruto M., Kishimoto T., Akira S. Phosphorylation at threonine-235 by a raj-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc. Natl. Acad. Sci. USA. 1993; 90: 2207–2211
   PubMed Web of Science ®Google Scholar
• Derijard B., Hibi M., Wu I.-H., Barrett T., Su B., Deng T., Karin M., Davis R. J. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 1994; 76: 1025–1037
   PubMed Web of Science ®Google Scholar
• Yamasaki K., Taga T., Hirata Y., Yawata H., Kawanishi Y., Seed B., Taniguchi T., Hirano T., Kishimoto T. Cloning and expression of the human interleukin-6 (BSF-2/IFNβ2) receptor. Science 1988; 241: 825–828
   PubMed Web of Science ®Google Scholar
• Hibi M., Murakami M., Saito M., Hirano T., Taga T., Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990; 63: 1149–1157
   PubMed Web of Science ®Google Scholar
• Ward L. D., Howlett G. J., Discolo G., Yasukawa K., Hammacher A., Moritz R. L., Simpson R. J. High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp130. J. Biol. Chem. 1994; 269: 23286–23289
   PubMed Web of Science ®Google Scholar
• Cosman D. The hematopoietin receptor superfamily. Cytokine 1993; 5: 95–106
   PubMed Web of Science ®Google Scholar
• Taga T., Kawanishi Y., Hardy R. R., Hirano T., Kishimoto T. Receptors for B-cell stimulatory factor 2. Quantitation, specifity, distribution, and regulation of their expression. J. Exp. Med. 1987; 166: 967–981
   PubMed Web of Science ®Google Scholar
• Suematsu S., Hibi M., Sugita T., Saito M., Murakami M., Matsusaka T., Matsuda T., Hirano T., Taga T., Kishimoto T. Interleukin 6 (IL-6) and its receptor (IL-6R) in myeloma/plasmacytoma. Curr. Top. Microbiol. Immunol. 1990; 166: 13–22
   PubMed Web of Science ®Google Scholar
• Jernberg-Wiklund H., Pettersson M., Carlsson M., Nilsson K. Increase in interleukin 6 (IL-6) and IL-6 receptor expression in a human multiple myeloma cell line, U-266, during long-term in vitro culture and the development of a possible autocrine IL-6 loop. Leukemia 1992; 6: 310–318
   PubMed Web of Science ®Google Scholar
• Taga T., Hibi M., Hirata Y., Yamasaki K., Yasukawa K., Matsuda T., Hirano T., Kishimoto T. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989; 58: 573–581
   PubMed Web of Science ®Google Scholar
• Murakami M., Hibi M., Nakagawa N., Nakagawa T., Yasukawa K., Yamanishi K., Taga T., Kishimoto T. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 1993; 260: 1808–1810
   PubMed Web of Science ®Google Scholar
• Darnell J. E., Jr, Kerr I. M., Stark G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415–1421
   PubMed Web of Science ®Google Scholar
• Gearing D. P., Comeau M. R., Friend D. J., Gimpel S. D., Thut C. J., McGourty J., Brasher K. K., King J. A., Gillis S., Mosley B., Ziegler S. F., Cosman D. The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science 1992; 255: 1434–1437
   PubMed Web of Science ®Google Scholar
• Lutticken C., Wegenka U. M., Yuan J., Buschmann J., Schindler C., Ziemiecki A., Harpur A. G., Wilks A. F., Yasukawa K., Taga T., Kishimoto T., Barbieri G., Pellegrini S., Sendtner M., Heinrich P. C., Horn F. Association of transcription factor APRF and protein kinase Jakl with the interleukin-6 signal transducer gp130. Science 1994; 263: 89–92
   PubMed Web of Science ®Google Scholar
• Stahl N., Boulton T. G., Farruggella T., Ip N. Y., Davis S., Witthuhn B. A., Quelle F. W., Silvennoinen O., Barbieri G., Pellegrini S., Ihle J. N., Yancopoulos G. D. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science 1994; 263: 92–95
   PubMed Web of Science ®Google Scholar
• Guschin D., Rogers N., Briscoe J., Witthuhn B., Watling D., Horn F., Pellegrini S., Yasukawa K., Heinrich P., Stark G. R., Ihle J. N., Kerr I. M. A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. EMBO J. 1995; 14: 1421–1429
   PubMed Web of Science ®Google Scholar
• Akira S., Nishio Y., Inoue M., Wang X.-J., Wei S., Matsusaka T., Yoshida K., Sudo T., Naruto M., Kishimoto T. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91 -related transcription factor involved in the gp 130-mediated signaling pathway. Cell 1994; 77: 63–71
   PubMed Web of Science ®Google Scholar
• Stahl N., Farruggella J., Boulton T. G., Zhong Z., Darnell J. E., Jr, Yancopoulos G. D. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 1995; 267: 1349–1353
   PubMed Web of Science ®Google Scholar
• Fukada T., Hibi M., Yamanaka Y., Takahashi-Tezuka M., Fujitani Y., Yamaguchi T., Nakajima K., Hirano T. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity 1996; 5: 449–460
   PubMed Web of Science ®Google Scholar
• Kumar G., Gupta S., Wang S., Nel A. E. Involvement of Janus kinases, p52shc, Raf-1, and MEK-1 in the IL-6-induced mitogen-activated protein kinase cascade of a growth-responsive B-cell line. J. Immunol. 1994; 153: 4436–4447
   PubMed Web of Science ®Google Scholar
• Berger L. C., Hawley R. G. Interferon-β interrupts-6-dependent signaling events in myeloma cells. Blood 1997; 89: 261–271
   PubMed Web of Science ®Google Scholar
• Daeipour M., Kumar G., Amaral M. C., Nel A. E. Recombinant IL-6 activates p42 and p44 mitogen-activated protein kinases in the IL-6-responsive B-cell line, AF-10. J. Immunol. 1993; 150: 4743–4753
   PubMed Web of Science ®Google Scholar
• Sabourin L. A., Hawley R. G. Suppression of programmed death and G1 arrest in B-cell hybridomas by interleukin-6 is not accompanied by altered expression of immediate early response genes. J. Cell. Physiol. 1990; 145: 564–574
   PubMed Web of Science ®Google Scholar
• Schwarze M. M. K., Hawley R. G. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin-6-mediated up-regulation of bcl-xL. Cancer Res. 1995; 55: 2262–2265
   PubMed Web of Science ®Google Scholar
• Nakajima K., Wall R. Interleukin-6 signals activating junB and TIS11 gene transcription in a B-cell hybridoma. Mol. Cell. Biol. 1991; 11: 1409–1418
   PubMed Web of Science ®Google Scholar
• Brenning G., Jernberg H., Gidlund M., Sjoeberg O., Nilson K. The effect of α and γ-interferon on proliferation and production of IgE and β₂-microglobulin in the human myeloma cell line U-266 and in an α-interferon resistant U-266 subline. 1986
   Google Scholar
• Portier M., Zhang X. G., Caron E., Lu Z. Y., Bataille R., Klein B. γ-Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. Blood 1993; 81: 3076–3082
   PubMed Web of Science ®Google Scholar
• Schwabe M., Brini A. T., Bosco M. C., Rubboli F., Egawa M., Zhao J., Princler G. L., Kung H. Disruption by interferon-α of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor α-and β-chains. J. Clin. Invest. 1994; 94: 2317–2325
   PubMed Web of Science ®Google Scholar
• Anthes J. C., Zhan Z., Gilchrest H., Egan R. W., Siegel M. I., Billah M. M. Inteferon-α down-regulates the interleukin-6 receptor in a human multiple myeloma cell line, U266. Biochem. J. 1995; 309: 175–180
   PubMed Web of Science ®Google Scholar
• Goto H., Shimazaki C., Tatsumi T., Yamagata N., Fujita N., Tsuchiya M., Koishihara Y., Ohsugi Y., Nakagawa M. Establishment of a novel myeloma cell line KPMM2 carrying t(3;14)(q21;q32), which proliferates specifically in response to interleukin-6 through an autocrine mechanism. Leukemia 1995; 9: 711–718
   PubMed Web of Science ®Google Scholar
• Westendorf J. J., Ahmann G. J., Greipp P. R., Witzig T. E., Lust J. A., Jelinek D. F. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia 1996; 10: 866–876
   PubMed Web of Science ®Google Scholar
• De Maeyer E., De Maeyer-Guignard J. Interferons and Other Regulatory Cytokines. John Wiley and Sons., New York 1988
   Google Scholar
• Brenning G., Ahre A., Nilsson K. Correlation between in vitro, in vivo sensitivity to human leucocyte interferon in patients with multiple myeloma. Scand. J. Haematol. 1985; 35: 543–549
   PubMedGoogle Scholar
• Brenning G. The in vitro effect of leucocyte α-interferon on human myeloma cells in a semisolid agar culture system. Scand. J. Haematol. 1985; 35: 178–185
   PubMedGoogle Scholar
• Jourdan M., Zhang X. G., Portier M., Boiron J.-M., Bataille R., Klein B. IFN-α induces autocrine production of IL-6 in myeloma cell lines. J. Immunol. 1991; 147: 4402–4407
   PubMed Web of Science ®Google Scholar
• Jemberg-Wiklund H., Pettersson M., Nilsson K. Recombinant interferon-γ inhibits the growth of IL-6-dependent human multiple myeloma cell lines in vitro. Eur. J. Haematol. 1991; 46: 231–239
   PubMed Web of Science ®Google Scholar
• Palumbo A., Battaglio S., Napoli P., Omede P., Fusaro A., Bruno B., Boccadoro M., Pileri A. Recombinant interferon-γ inhibits the in vitro proliferation of human myeloma cells. Br. J. Haematol 1994; 86: 726–732
   PubMed Web of Science ®Google Scholar
• Uze G., Lutfalla G., Mogensen K. E. α and β interferons and their receptor and their friends and relations. J. Interferon Cytokine Res. 1995; 15: 3–26
   PubMed Web of Science ®Google Scholar
• Uze G., Lutfalla G., Gresser I. Genetic transfer of a functional human interferon-α receptor into mouse cells: cloning and expression of its cDNA. Cell 1990; 60: 225–234
   PubMed Web of Science ®Google Scholar
• Domanski P., Witte M., Kellum M., Rubinstein M., Hackett R., Pitha P., Colamonici O. R. Cloning and expression of a long form of the β subunit of the interferon-α/β receptor that is required for signaling. J. Biol. Chem. 1995; 270: 21606–21611
   PubMed Web of Science ®Google Scholar
• Muller M., Briscoe J., Laxton C., Guschin D., Ziemiecki A., Silvennoinen O., Harpur A. G., Barbieri G., Wilks A. F., Ihle J. N., Stark G. R., Kerr I. M. The protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transduction. Nature 1993; 366: 129–135
   PubMed Web of Science ®Google Scholar
• Muller M., Laxton C., Briscoe J., Schindler C., Improta T., Dernell J. E., Jr, Stark G. R., Kerr I. M. Complementation of a mutant cell line: central role of the 91 kDA polypeptide of ISGF3 in the interferon-α and -γ signal transduction pathways. EMBO J. 1993; 12: 4221–4228
   PubMed Web of Science ®Google Scholar
• Colamonici O. R., Uyttendaele H., Domanski P., Yan H., Krolewski J. J. p135tyk2, an interferon-α-activated tyrosine kinase, is physically associated with an interferon-α receptor. J. Biol. Chem. 1994; 269: 3518–3522
   PubMed Web of Science ®Google Scholar
• Colamonici O. R., Platanias L. C., Domanski P., Handa R., Gilmour K. C., Diaz M. O. Transmembrane signaling by the α subunit of the type I interferon receptor is essential for activation of the JAK kinases and the transcriptional factor ISGF3. J. Biol. Chem. 1995; 270: 8188–8193
   PubMed Web of Science ®Google Scholar
• Yan H., Krishnan K., Lim J. T., Contillo L. G., Krolewski J. J. Molecular characterization of an α-interferon receptor 1 subunit (IFNaRl) domain required for TYK2 binding and signal transduction. Mol. Cell. Biol. 1996; 16: 2074–2082
   PubMed Web of Science ®Google Scholar
• Novick D., Cohen B., Rubinstein M. The human interferon-α/β receptor: characterization and molecular cloning. Cell 1994; 77: 391–400
   PubMed Web of Science ®Google Scholar
• Greenlund A. C., Morales M. O., Viviano B. L., Yan H., Krolewski J., Schreiber R. D. Stat recruitment by tyrosine-phosphorylated cytokine receptors: an ordered reversible affinity-driven process. Immunity 1995; 2: 677–687
   PubMed Web of Science ®Google Scholar
• Yan H., Krishnan K., Greenlund A. C., Gupta S., Lim J. T., Schreiber R. D., Schindler C. W., Krolewski J. J. Phosphorylated interferon-α receptor 1 subunit (IFNaR1) acts as a docking site for the latent form of the 113 kDa STAT2 protein. EMBO J. 1996; 15: 1064–1074
   PubMed Web of Science ®Google Scholar
• Li X., Leung S., Kerr I. M., Stark G. R. Functional subdomains of STAT2 required forpreassociation with the α-interferon receptor and for signaling. Mol. Cell. Biol. 1997; 17: 2048–2056
   PubMed Web of Science ®Google Scholar
• Schindler C., Darnell J. E., Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Ann. Rev. Biochem. 1995; 64: 621–651
   PubMed Web of Science ®Google Scholar
• Platanias L. C., Uddin S., Domanski P., Colamonici O. R. Differences in interferon α and β signaling. Interferon β selectively induces the interaction of the α nd βL subunits of the type I interferon. J. Biol. Chem. 1996; 271: 23630–23633
   PubMed Web of Science ®Google Scholar
• Croze E., Russell-Harde D., Wagner T. C., Pu H., Pfeffer L. M., Perez H. D. The human type I interferon receptor. Identification of the interferon β-specific receptor-associated phosphoprotein. J. Biol. Chem. 1996; 271: 33165–33168
   PubMed Web of Science ®Google Scholar
• Aguet M., Dembic Z., Merlin G. Molecular cloning and expression of the human interferon-γ receptor. Cell 1988; 55: 273–280
   PubMed Web of Science ®Google Scholar
• Farrar M. A., Schreiber P. D. The molecular cell biology of interferon-γ and its receptor. Ann. Rev. Immunol. 1993; 11: 571–611
   PubMed Web of Science ®Google Scholar
• Schindler C., Shuai K., Prezioso V. R., Darnell J. E., Jr. Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science 1992; 257: 809–813
   PubMed Web of Science ®Google Scholar
• Shuai K., Schindler C., Prezioso V. R., Darnell J. E., Jr. Activation of transcription by IFN-γ: tyrosine phosphorylation of a 91-kD DNA binding protein. Science 1992; 258: 1808–1812
   PubMed Web of Science ®Google Scholar
• Greenlund A. C., Farrar M. A., Viviano B. L., Schreiber R. D. Ligand-induced IFN-γreceptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91). EMBO J. 1994; 13: 1591–1600
   PubMed Web of Science ®Google Scholar
• Watling D., Guschin D., Muller M., Silvennoinen O., Witthuhn B. A., Quelle F. W., Rogers N. C., Schindler C., Stark G. R., Ihle J. N., Kerr I. M. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-γ signal transduction pathway. Nature 1993; 366: 166–170
   PubMed Web of Science ®Google Scholar
• Shuai K., Horvath C. M., Tsai Huang L. H., Qureshi S. A., Cowburn D., Darnell J. E., Jr. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 1994; 76: 821–828
   PubMed Web of Science ®Google Scholar
• Schwab G., Siegall C. B., Aarden L. A., Neckers L. M., Nordan R. P. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood 1991; 77: 587–593
   PubMed Web of Science ®Google Scholar
• Lasfar A., Wietzerbin J., Billard C. Differential regulation of interleukin-6 receptors by interleukin-6 and interferons in multiple myeloma cell lines. Eur. J. Immunol. 1994; 24: 124–130
   PubMed Web of Science ®Google Scholar
• Schwabe M., Zhao J., Kung H. Differential expression and ligand-induced modulation of the human interleukin-6 receptor on interleukin-6-responsive cells. J. Biol. Chem. 1994; 269: 7201–7209
   PubMed Web of Science ®Google Scholar
• Ogata A., Nishimoto N., Shima Y., Yoshizaki K., Kishimoto T. Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction. Blood 1994; 84: 3040–3046
   PubMed Web of Science ®Google Scholar
• Cook S. J., McCormick F. Inhibition by cAMP on Ras-dependent activation of Raf. Science 1993; 262: 1069–1072
   PubMed Web of Science ®Google Scholar
• Marx J. Two major signal pathways linked. Science 1993; 262: 988–990
   PubMed Web of Science ®Google Scholar
• Xu J., Rockow S., Kim S., Xiong W., Li W. Interferons block protein kinase C-dependent but not -independent activation of Raf-1 and mitogen-activated protein kinases and mitogenesis in NIH 3T3 cells. Mol. Cell. Biol. 1994; 14: 8018–8027
   PubMed Web of Science ®Google Scholar
• Rezzonico R., Loubat A., Lallemand D., Pfarr C. M., Far D. F., Proudfoot A., Rossi B., Ponzio G. Cyclic AMP stimulates a JunD/Fra-2 AP-1 complex and inhibits the proliferation of interleukin-6-dependent cell lines. Oncogene 1995; 11: 1069–1078
   PubMed Web of Science ®Google Scholar
• Hsu W., Kerppola T. K., Chen P.-L., Curran T., Chen-Kiang S. Fos and Jun repress transcription activation by NF-IL6 through association at the basic zipper region. Mol. Cell. Biol. 1994; 14: 268–276
   PubMed Web of Science ®Google Scholar
• David M., Petricoin E., III, Lamer A. C. Activation of protein kinase A inhibits interferon induction of the Jak/Stat pathway in U266 cells. J. Biol. Chem. 1996; 271: 4585–4588
   PubMed Web of Science ®Google Scholar
• David M., Petricoin E., III, Benjamin C., Pine R., Weber M. J., Lamer A. C. Requirement for MAP kinase (ERK2) activity in interferon α-and interferon β-stimulated gene expression through STAT proteins. Science 1995; 269: 1721–1723
   PubMed Web of Science ®Google Scholar
• Zhang X., Blenis J., Li H.-C., Schindler C., Chen-Kiang S. Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science 1995; 267: 1990–1994
   PubMedGoogle Scholar
• David M., Zhou G., Pine R., Dixon J. E., Lamer A. C. The SH2 domain-containing tyrosine phosphatase PTP1D is required for interferon α/β-induced gene expression. J. Biol. Chem. 1996; 271: 15862–15865
   PubMed Web of Science ®Google Scholar
• Berger L. C., Tamir A., Ben-David Y., Hawley R. G. Dose-dependent activation of p21ras by interferon-β. J. Interferon Cytokine Res. 1997, In press.
   PubMedGoogle Scholar
• Rodriguez-Viciana P., Warne P. H., Dhand R., Vanhaesebroeck B., Gout I., Fry M. J., Waterfield M. D., Downward J. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994; 370: 527–532
   PubMed Web of Science ®Google Scholar
• Uddin S., Fish E. N., Sher D. A., Gardziola C., White M. F., Platanias L. C. Activation of the phosphatidylinositol 3-kinase serine kinase by IFN-α. J. Immunol. 1997; 158: 2390–2397
   PubMed Web of Science ®Google Scholar
• Hu Q., Klippel A., Muslin A. J., Fantl W. J., Williams L. T. Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. Science 1995; 268: 100–102
   PubMed Web of Science ®Google Scholar
• Yao R., Cooper G. M. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 1995; 267: 2003–2006
   PubMed Web of Science ®Google Scholar
• Datta K., Bellacosa A., Chan T. O., Tsichlis P. N. Akt is a direct target of the phosphatidylinositol 3-kinase. Activation by growth factors, v-scr and v-Ha-ras, in Sf9 and mammalian cells. J. Biol. Chem. 1996; 271: 30835–30839
   PubMed Web of Science ®Google Scholar
• Kauffmann-Zeh A., Rodriguez-Viciana P., Ulrich E., Gilbert C., Coffer P., Downward J., Evan G. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 1997; 385: 544–548
   PubMed Web of Science ®Google Scholar
• Egle A., Villunger A., Kos M., Bock G., Gruber J., Auer B., Greil R. Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-α2. Eur. J. Immunol. 1996; 26: 3119–3126
   PubMed Web of Science ®Google Scholar
• Ferlin-Bezombes M., Jourdan M., Brochier J., Liautard J., Rossi J.-F., Klein B. Interferon-α is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis. 1997, Manuscript submitted.
   Google Scholar
• Soldi R., Graziani A., Benelli R., Ghigo D., Bosia A., Albini A., Bussolino F. Oncostatin M activates phoshphatidylinositol-3-kinase in Kaposi's sarcoma cells. Oncogene 1994; 9: 2253–2260
   PubMed Web of Science ®Google Scholar
• Yang C. H., Shi W., Basu L., Murti A., Constantinescu S. N., Blatt L., Croze E., Mullersman J. E., Pfeffer L. M. Direct association of STAT3 with the IFNAR-1 chain of the human type I interferon receptor. J. Biol. Chem. 1996; 271: 8057–8061
   PubMed Web of Science ®Google Scholar
• Pfeffer L. M., Mullersman J. E., Pfeffer S. R., Murti A., Shi W., Yang C. H. STAT3 as an adapter to couple phosphatidylinositol 3-kinase to the IFNAR1 chain of the type I interferon receptor. Science 1997; 276: 1418–1420
   PubMed Web of Science ®Google Scholar
• Raveh T., Hovanessian A. G., Meurs E. F., Sonenberg N., Kimchi A. Double-stranded RNA-dependent protein kinase mediates c-Myc suppression induced by type I interferons. J. Biol. Chem. 1996; 271: 25479–25484
   PubMed Web of Science ®Google Scholar
• Kuhen K. L., Samuel C. E. Isolation of the interferon-inducible RNA-dependent protein kinase Pkr promoter and identification of a novel DNA element within the 5′-flanking region of human and mouse Pkr genes. Virology 1997; 227: 119–130
   PubMed Web of Science ®Google Scholar
• Chin Y. E., Kitagawa M., Su W.-C. S., You Z.-H., Iwamoto Y., Fu X.-Y. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21WAF1/CIPI mediated by STAT1. Science 1996; 272: 719–722
   PubMed Web of Science ®Google Scholar
• Resnitzky D., Tiefenbrun N., Berissi H., Kimchi A. Interferons and interleukin 6 suppress phosphorylation of the retinoblastoma protein in growth-sensitive hematopoietic cells. Proc. Natl. Acad. Sci. USA 1992; 89: 402–406
   PubMed Web of Science ®Google Scholar
• Choubey D., Lengyel P. Binding of an interferon-inducible protein (p202) to the retinoblastoma protein. J. Biol. Chem. 1995; 270: 6134–6140
   PubMed Web of Science ®Google Scholar
• Juge-Morineau N., Harousseau J.-L., Amiot M., Bataille R. The retinoblastoma susceptibility gene RB-1 in multiple myeloma. Leuk. Lymphoma 1997; 24: 229–237
   PubMed Web of Science ®Google Scholar
• Stewart A. K., Meharchand J., Dube I. D., Graham F. L., Gauldie J., Hawley R. G. A phase I study of autologous gene modified plasma cell vaccination following peripheral blood stem cell transplantation for the control of minimal residual myeloma. Therapeutic Products Directorate, Health Protection Branch, Health Canada. Control No. 049780., 1997
   Google Scholar
• Stewart A. K., Hawley R. G. Adenovirus-mediated immunogene therapy for the treatment of myeloma: pre-clinical and clinical studies. VI International Workshop on Multiple Myeloma. Cancer Treat. Rep. 1997, In press.
   Google Scholar
• Nastala C. L., Edington H. D., McKinney T. G., Tahara H., Nalesnik M. A., Brunda M. J., Gately M. K., Wolf S. F., Schreiber R. D., Storkus W. J., Lotze M. T. Recombinant IL-12 administration induces tumor regression in association with IFNγ production. J. Immunol. 1994; 153: 1697–1706
   PubMed Web of Science ®Google Scholar
• Kerbel R. S., Hawley R. G. Interleukin 12: newest member of the antiangiogenesis club. J. Natl. Cancer Inst. 1995; 87: 557–559
   PubMed Web of Science ®Google Scholar
• Hawley R. G., Lieu F. H. L., Fong A. Z. C., Goldman S. J., Leonard J. P., Hawley T. S. Retroviral vectors for production of interleukin-12 in the bone marrow to induce a graft-versus-leukemia effect. Ann. N.Y. Acad. Sci. 1996; 795: 341–345
   PubMed Web of Science ®Google Scholar
• Lieu F. H. L., Hawley T. S., Fong A. Z. C., Hawley R. G. Transmissibility of MSCV-based retroviral vectors carrying both interleukin-12 cDNAs and a third gene: implications for immune gene therapy. Cancer Gene Ther. 1997; 4: 167–175
   PubMed Web of Science ®Google Scholar